Biogen

BIIB Healthcare & Pharma 1/10 Low Risk
1/10
— 1 → 1 over 6 weeks
Sector avg: 2.8/10

Biogen carries $6.3B in long-term debt, with $6.6B in scheduled principal maturities. DebtCanary scores BIIB at 1/10, suggesting manageable refinancing risk.

Maturity Schedule

Year 1 $0 Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $1.5B Beyond 5 $5.1B
Period Amount Due % of Total
Year 1 (0-12 months) $0 0.0%
Year 2 (12-24 months) $0 0.0%
Year 3 (24-36 months) $0 0.0%
Year 4 (36-48 months) $0 0.0%
Year 5 (48-60 months) $1.5B 22.8%
Beyond 5 Years $5.1B 77.2%
Total Scheduled Maturities $6.6B 100.0%

Key Metrics

Total Long-Term Debt
$6.3B
Near-Term (12mo)
$0
Interest Coverage
N/A
Debt/Equity
0.42
Cash Coverage
N/A
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 0.0% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 0.42 25%
Cash Coverage of Near-Term Debt N/A 20%

Recent SEC Filings

Material disclosures from Biogen's most recent EDGAR filings. 8-K item labels indicate the type of event reported.

Date Form Details
2026-04-28 DEFA14A Additional proxy materials
2026-04-28 DEF 14A Proxy statement
2026-04-06 8-K Earnings Results
2026-03-31 8-K Material Agreement, Other Events
2026-03-11 8-K Officer / Director Change
2026-02-11 8-K Officer / Director Change, Other Events
2026-02-06 10-K Annual report
2026-02-06 8-K Earnings Results

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Eli Lilly
LLY
3/10
Debt: $29.5B 12mo: $781M
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-06. Data last fetched: 2026-04-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Biogen →